The Breast Journal / 2022 / Article / Tab 3 / Research Article
Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study Table 3 Multivariate survival analysis of prognostic factors among BC patients.
Cox-OS Cox-BCSS Fine–Gray CS HR 95% CI HR 95% CI HR — HR — Year of diagnosis < 0.001 <0.001 2000–2003 vs. 2008–2015 1.427 1.382–1.472 <0.001 1.914 1.832–1.999 <0.001 1.607 1.539–1.678 <0.001 1.557 1.491–1.625 <0.001 2004–2007 vs. 2008–2015 1.196 1.158–1.234 <0.001 1.329 1.272–1.389 <0.001 1.226 1.173–1.282 <0.001 1.202 1.150–1.258 <0.001 Age, years <0.001 <0.001 64–72 vs. 18–63 2.388 2.318–2.459 <0.001 1.595 1.525–1.667 <0.001 1.314 1.256–1.374 <0.001 1.394 1.333–1.457 <0.001 73–79 vs. 18–63 4.891 4.744–5.043 <0.001 2.877 2.730–3.033 <0.001 1.662 1.574–1.755 <0.001 1.955 1.855–2.061 <0.001 Race <0.001 <0.001 Black vs. white 1.378 1.329–1.429 <0.001 1.343 1.279–1.411 <0.001 1.291 1.227–1.359 <0.001 1.318 1.255–1.384 <0.001 Others vs. white 0.711 0.677–0.748 <0.001 0.762 0.712–0.815 <0.001 0.800 0.747–0.856 <0.001 0.788 0.737–0.843 <0.001 Histology type ILC vs. IDC 0.906 0.864–0.949 <0.001 — — 0.844 — — 0.278 — — 0.474 Laterality Right vs. Left 0.967 0.944–0.990 0.005 0.946 0.915–0.979 0.002 0.947 0.915–0.981 0.002 0.946 0.914–0.979 0.001 Grade <0.001 <0.001 II vs. I 1.180 1.139–1.223 <0.001 1.958 1.820–2.107 <0.001 1.943 1.807–2.089 <0.001 1.951 1.813–2.100 <0.001 III/IV vs. I 1.430 1.374–1.488 <0.001 2.719 2.521–2.933 <0.001 2.676 2.480–2.888 <0.001 2.703 2.505–2.916 <0.001 T stage <0.001 <0.001 T1b vs. T1a 1.240 1.161–1.325 <0.001 1.225 1.070–1.402 0.003 1.175 1.027–1.344 0.019 1.191 1.041–1,363 0.011 T1c vs. T1a 1.565 1.471–1.666 <0.001 2.177 1.924–2.464 <0.001 2.028 1.792–2.294 <0.001 2.084 1.842–2.359 <0.001 T2 vs. T1a 2.306 2.163–2.458 <0.001 3.779 3.339–4.278 <0.001 3.470 3.065–3.929 <0.001 3.615 3.193–4.092 <0.001 N stage <0.001 <0.001 N1 vs. N0 1.496 1.453–1.540 <0.001 1.958 1.880–2.038 <0.001 1.923 1.845–2.004 <0.001 1.948 1.870–2.028 <0.001 N2 vs. N0 2.617 2.494–2.746 <0.001 3.742 3.529–3.968 <0.001 3.565 3.352–3.792 < 0.001 3.705 3.494–3.929 <0.001 N3 vs. N0 4.340 4.084–4.611 <0.001 6.276 5.854–6.729 <0.001 5.985 5.546–6.459 <0.001 6.306 5.882–6.760 <0.001 ER Positive vs. negative 0.832 0.800–0.865 <0.001 0.789 0.749–0.832 <0.001 0.792 0.749–0.838 <0.001 0.790 0.749–0.833 <0.001 PR Positive vs. negative 0.834 0.806–0.862 <0.001 0.716 0.681–0.752 <0.001 0.723 0.687–0.761 <0.001 0.717 0.683–0.754 <0.001 Treatment BCT vs. mastectomy 0.764 0.745–0.783 <0.001 0.760 0.734–0.787 <0.001 0.807 0.779–0.837 <0.001 0.784 0.757–0.812 <0.001 Chemotherapy Yes vs. no or unknown 0.779 0.757–0.803 <0.001 0.955 0.916–0.996 0.032 – – 0.063 – – 0.928
HR, hazard ratio; CI, confidence interval; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; BCT, breast-conserving therapy.
